Medical Pharmacology: Chapter 7: Hypertension — Clinical and Pharmacological Series -- Module: HTN-01 — Definition, Classification, and Pathophysiology

Chapter 7: Hypertension — Clinical and Pharmacological Series — Module: HTN-01 — Definition, Classification, and Pathophysiology
Tier: Tier 4

CASE 1

Mr. R.T. is a 54-year-old African American man who presents to his primary care physician for a routine visit. He has no known medical history and takes no medications. Blood pressure measured on two separate occasions today is 158/96 mmHg. He is 5'11", weighs 218 pounds (BMI 30.4), works as a long-haul truck driver, sleeps 5–6 hours per night, and reports heavy snoring. His wife has noted witnessed apneas. He does not smoke and drinks two to three beers on weekends. Fasting labs: glucose 101 mg/dL, potassium 3.8 mEq/L, creatinine 1.0 mg/dL, eGFR (estimated glomerular filtration rate) 88 mL/min/1.73m², sodium 140 mEq/L, LDL (low-density lipoprotein) 138 mg/dL, HDL (high-density lipoprotein) 44 mg/dL. His 10-year atherosclerotic cardiovascular disease risk (ASCVD risk) calculated using the Pooled Cohort Equations is 13%.

1. [CASE 1 — QUESTION 1] Under the 2017 ACC/AHA guidelines, how should Mr. R.T.'s blood pressure be classified, and what is the most appropriate initial management strategy given his risk profile?

A) Elevated blood pressure; lifestyle modification only is appropriate because his systolic pressure is below 160 mmHg
B) Stage 1 hypertension; lifestyle modification alone is appropriate because his ASCVD risk, while above 10%, does not meet the threshold for mandatory pharmacotherapy at this blood pressure level
C) Stage 2 hypertension; initiate dual antihypertensive therapy immediately given the degree of elevation and his cardiovascular risk
D) Stage 1 hypertension; pharmacotherapy is indicated in addition to lifestyle modification because his 10-year ASCVD risk of 13% exceeds the 10% threshold that triggers drug treatment at Stage 1, and his comorbidity burden (obesity, probable obstructive sleep apnea, borderline glucose) reinforces the urgency of BP control
E) Stage 2 hypertension; defer pharmacotherapy and refer first to a sleep medicine specialist since obstructive sleep apnea is the most likely cause of his hypertension and continuous positive airway pressure (CPAP) (continuous positive airway pressure) therapy alone will normalize his BP

ANSWER: C

Rationale:

This question asked you to classify Mr. R.T.'s BP and determine initial management.

Option C: Option C is correct: at 158/96 mmHg, Mr. R.T. meets Stage 2 hypertension criteria (systolic ≥140 mmHg OR diastolic ≥90 mmHg under 2017 ACC/AHA guidelines). At Stage 2, pharmacotherapy is indicated regardless of ASCVD risk — the threshold for drug treatment at Stage 2 does not require the 10% ASCVD risk calculation that applies to Stage 1 decisions. With a 10-year ASCVD risk of 13%, established obesity, probable obstructive sleep apnea (OSA), and borderline fasting glucose suggesting early insulin resistance, the urgency of BP control is reinforced. The 2017 guidelines recommend initiating pharmacotherapy at Stage 2, either as monotherapy for mild Stage 2 or dual therapy for higher Stage 2 values. At 158/96 with multiple risk amplifiers, dual therapy is appropriate.
Option A: Option A misclassifies the BP as merely elevated — elevated BP is systolic 120–129 with diastolic below 80.
Option B: Option B misclassifies as Stage 1 and incorrectly applies the ASCVD risk threshold that governs Stage 1 decisions.
Option D: Option D misclassifies as Stage 1 despite the systolic of 158 mmHg and diastolic of 96 mmHg clearly exceeding Stage 2 thresholds.
Option E: Option E correctly identifies Stage 2 but incorrectly defers pharmacotherapy pending OSA evaluation — while CPAP therapy does reduce BP in OSA, it cannot be relied upon as sole management and pharmacotherapy should not be withheld while awaiting sleep medicine consultation.

2. [CASE 1 — QUESTION 2] His physician elects to start antihypertensive therapy. Given his ethnic background, the trial evidence regarding differential drug response, and the absence of compelling comorbid indications for a specific agent, which initial drug class or combination is most consistent with current evidence-based recommendations for a Black patient with Stage 2 hypertension?

A) ACE inhibitor monotherapy, because RAAS blockade is the most evidence-based first-line therapy regardless of race or renin status
B) Beta-blocker monotherapy, because his sympathetic nervous system (SNS) overactivation from OSA and obesity makes beta-1 selective blockade the most mechanistically targeted initial therapy
C) A thiazide-like diuretic such as chlorthalidone plus a dihydropyridine calcium channel blocker (CCB) such as amlodipine, because Black patients have a higher prevalence of low-renin, volume-dependent hypertension and show attenuated BP response to ACE inhibitor monotherapy; thiazides and CCBs are effective regardless of renin status and are preferred as initial therapy in this population
D) ARB monotherapy, because ARBs avoid the bradykinin-mediated cough of ACE inhibitors and are equally effective across all racial groups without the differential response seen with ACE inhibitors
E) Spironolactone monotherapy, because his presentation is consistent with primary aldosteronism and empiric mineralocorticoid receptor antagonism is the most appropriate initial therapy before formal workup

ANSWER: C

Rationale:

This question asked you to apply the evidence regarding differential antihypertensive response in Black patients to initial drug selection. Option C is correct: multiple landmark trials including ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) demonstrated that Black patients with hypertension show attenuated blood pressure response to ACE inhibitor monotherapy compared to thiazide diuretics and CCBs. The mechanistic basis is a higher prevalence of low-renin, volume-dependent hypertension in this population — when renin is already suppressed, further RAAS blockade through ACE inhibition produces less incremental BP reduction as monotherapy. Thiazide-like diuretics (chlorthalidone preferred over hydrochlorothiazide for cardiovascular outcome data) and dihydropyridine CCBs are effective regardless of renin status because they reduce BP through volume reduction and direct vasodilation respectively. The 2017 ACC/AHA guidelines recommend initial therapy with a thiazide diuretic, CCB, ACE inhibitor, or ARB for most patients, but note that in Black patients without CKD or heart failure, initial therapy with a thiazide or CCB is preferred. At Stage 2, combination therapy is appropriate.

Option A: Option A is incorrect — ACE inhibitor monotherapy is specifically less effective as initial therapy in Black patients without CKD or heart failure and is not the preferred first choice.
Option B: Option B is incorrect — beta-blockers are not recommended as first-line antihypertensives in uncomplicated hypertension; while OSA does increase SNS activation, a beta-blocker is not the evidence-based initial choice here.
Option D: Option D is incorrect — while ARBs avoid ACE inhibitor cough, they share the same mechanistic limitation as ACE inhibitors in low-renin hypertension and are not preferred as initial monotherapy over thiazide/CCB in this population.
Option E: Option E is incorrect — there is no biochemical evidence of primary aldosteronism (his potassium is normal, no suppressed renin or elevated aldosterone-to-renin ratio (ARR) documented); empiric spironolactone is not indicated.

3. [CASE 1 — QUESTION 3] Mr. R.T. is started on chlorthalidone 12.5 mg and amlodipine 5 mg daily. At 6-week follow-up, his BP is 142/88 mmHg — improved but not at goal. His physician increases both agents to maximum doses (chlorthalidone 25 mg, amlodipine 10 mg). At 3-month follow-up, BP is 138/86 mmHg and he has undergone polysomnography (sleep study) confirming severe OSA with an apnea-hypopnea index of 42 events per hour. He has been started on CPAP. Which of the following best explains why achieving BP goal may still require adding a third antihypertensive agent even with CPAP therapy initiated?

A) CPAP therapy is contraindicated in patients on amlodipine because positive airway pressure increases venous return and exacerbates CCB-mediated peripheral vasodilation, producing dangerous hypotension during sleep
B) Adding a second diuretic such as furosemide is the appropriate next step because the residual BP elevation reflects volume expansion from OSA-mediated aldosterone excess that chlorthalidone alone cannot overcome
C) CPAP therapy is ineffective in truck drivers because occupational sleep disruption prevents adequate mask compliance during the required 7–8 hours of continuous CPAP use, and only surgical intervention for OSA will produce sufficient BP reduction
D) The residual hypertension reflects thiazide-induced hyperuricemia activating the xanthine oxidase pathway to produce vascular superoxide, which scavenges nitric oxide and sustains endothelial dysfunction — stopping chlorthalidone and substituting a RAAS inhibitor will correct this
E) While CPAP reduces BP by interrupting the nocturnal sympathetic surges, daytime SNS hyperactivation, renin-angiotensin-aldosterone system (RAAS) upregulation, and hypoxia-driven aldosterone excess that OSA produces persist beyond what CPAP alone can fully reverse — particularly in a patient with concurrent obesity and insulin resistance who has multiple independent mechanisms sustaining hypertension; a RAAS inhibitor would address the neurohormonal activation inadequately controlled by the current two-drug regimen

ANSWER: E

Rationale:

This question asked you to reason through why BP remains above goal despite two antihypertensives and new CPAP therapy. Option E is correct: while CPAP therapy does reduce BP in OSA by interrupting the repetitive nocturnal hypoxemia that drives sympathetic surges, the benefit is partial and varies by individual. In a patient with concurrent obesity, insulin resistance, borderline glucose, and high ASCVD risk, multiple independent neurohormonal mechanisms sustain hypertension beyond OSA alone. Hyperinsulinemia activates the SNS and promotes renal sodium retention; obesity drives leptin-mediated sympathoexcitation; RAAS upregulation from both OSA and obesity produces aldosterone excess that neither chlorthalidone nor amlodipine directly addresses at the receptor level. A RAAS inhibitor — ACE inhibitor or ARB — as the third agent would address these mechanisms while also providing renal protection in a patient with borderline metabolic syndrome. The combination of a thiazide, a CCB, and a RAAS inhibitor is the standard three-drug regimen for resistant or difficult-to-control hypertension.

Option A: Option A is incorrect — CPAP therapy is not contraindicated with amlodipine; there is no clinically significant interaction between positive airway pressure and CCBs.
Option C: Option C is incorrect — CPAP compliance challenges are real in this population but do not constitute a contraindication to CPAP; the physiological reasoning is also fabricated.
Option D: Option D is incorrect — while thiazide-induced hyperuricemia is a real metabolic effect and uric acid does have some oxidative activity, this is not the primary explanation for residual hypertension and stopping chlorthalidone is not the indicated response.
Option B: Option B is incorrect — while adding a loop diuretic could provide additional volume reduction, it is not the preferred third agent and does not address the RAAS and neurohormonal mechanisms that are the primary drivers of residual hypertension in this patient.

4. [CASE 1 — QUESTION 4] Mr. R.T. is added lisinopril 10 mg daily. At his next visit, his potassium has risen from 3.8 to 4.6 mEq/L and creatinine from 1.0 to 1.2 mg/dL. His BP is 128/78 mmHg — at goal. He asks whether these lab changes mean the medication is "hurting his kidneys." Which of the following most accurately addresses his concern?

A) The creatinine rise confirms early ACE inhibitor nephrotoxicity and lisinopril should be reduced to 5 mg to prevent further renal damage
B) The potassium rise to 4.6 mEq/L is dangerously elevated and requires immediate emergency management before his next scheduled visit
C) Both changes are expected pharmacodynamic effects of ACE inhibition — the modest creatinine rise (20% from baseline, well within the acceptable threshold of 30%) reflects the intended reduction in intraglomerular pressure from efferent arteriole vasodilation, and the mild potassium rise reflects reduced aldosterone-mediated potassium excretion; both are markers that the drug is working as intended, not signs of renal injury, and do not require dose reduction or discontinuation at these levels
D) The potassium rise reflects an ACE inhibitor–chlorthalidone interaction in which thiazide-mediated potassium wasting is paradoxically reversed by ACE inhibition through a mechanism unique to this combination at high doses
E) The creatinine and potassium changes indicate the lisinopril dose should be doubled to 20 mg because partial RAAS blockade at 10 mg produces the worst hemodynamic profile — full blockade at 20 mg will stabilize both values

ANSWER: C

Rationale:

This question asked you to interpret expected pharmacodynamic changes after ACE inhibitor initiation and communicate them accurately to the patient. Option C is correct: both laboratory changes are anticipated pharmacodynamic effects of ACE inhibition, not signs of kidney damage. The creatinine rise from 1.0 to 1.2 mg/dL represents a 20% increase — within the accepted threshold of approximately 30% above baseline, beyond which concern for bilateral renal artery stenosis or significant renovascular disease is raised. This rise reflects the reduced intraglomerular hydraulic pressure that results from efferent arteriole vasodilation — the very mechanism responsible for the drug's renal protective effect in the long term. The potassium rise from 3.8 to 4.6 mEq/L reflects reduced aldosterone-mediated potassium excretion in the collecting duct; 4.6 mEq/L is within the normal range and requires no intervention beyond monitoring. Reassuring Mr. R.T. that these changes indicate the medication is working as intended — and that his kidneys are being protected, not damaged — is both accurate and important for medication adherence.

Option A: Option A is incorrect — a 20% creatinine rise at the lower end of the acceptable range does not indicate nephrotoxicity or require dose reduction.
Option B: Option B is incorrect — a potassium of 4.6 mEq/L is within the normal range (3.5–5.0 mEq/L) and does not require emergency management.
Option D: Option D is incorrect — there is no paradoxical mechanism by which ACE inhibition reverses thiazide-mediated potassium wasting through a drug-interaction unique to this combination; ACE inhibition raises potassium by reducing aldosterone, which is a direct pharmacodynamic effect.
Option E: Option E is incorrect — doubling the dose is not indicated when the current dose has achieved BP goal and laboratory parameters are within acceptable ranges.

CASE 2

Ms. K.M. is a 67-year-old woman with a 20-year history of hypertension and type 2 diabetes, now presenting for urgent evaluation after her home blood pressure readings over the past week have been consistently above 170/100 mmHg. Her current medications include metformin 1000 mg twice daily, atorvastatin 40 mg, lisinopril 40 mg daily, and amlodipine 10 mg daily. She denies missing doses. BP in the office today is 174/102 mmHg. Recent labs (2 weeks ago): creatinine 1.4 mg/dL, eGFR 42 mL/min/1.73m², potassium 4.8 mEq/L, urine albumin-to-creatinine ratio (ACR) 340 mg/g. She was recently started on ibuprofen 600 mg three times daily by an orthopedist for knee osteoarthritis. She also started a nasal decongestant (pseudoephedrine) for sinus congestion 10 days ago.

5. [CASE 2 — QUESTION 1] Which of the following most accurately identifies the most likely pharmacological contributors to her worsening blood pressure control?

A) Ibuprofen inhibits cyclooxygenase (COX)-mediated renal prostaglandin synthesis, causing sodium and water retention and blunting the antihypertensive effect of her lisinopril and amlodipine; pseudoephedrine causes direct sympathomimetic vasoconstriction and is a recognized cause of drug-induced hypertension — both agents are contributing
B) Her lisinopril dose of 40 mg has reached a ceiling effect and is now causing paradoxical BP elevation through RAAS overstimulation; the dose should be halved
C) Her metformin dose is contributing to hypertension through mitochondrial complex I inhibition in vascular smooth muscle, increasing peripheral vascular resistance
D) Her amlodipine has lost efficacy due to pharmacokinetic tolerance — CCBs downregulate L-type calcium channels with chronic use, producing tachyphylaxis that requires switching to a different CCB
E) Atorvastatin is causing hypertension through HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibition in endothelial cells, reducing nitric oxide (NO) synthesis and increasing vascular tone at the doses used for secondary prevention

ANSWER: A

Rationale:

This question asked you to identify the pharmacological contributors to worsening BP control in a patient who has added new medications. Option A is correct: two recently added drugs are the most likely culprits. Ibuprofen — a non-selective NSAID — inhibits COX enzymes in the kidney, reducing synthesis of prostaglandin E2 and prostacyclin, which are vasodilatory prostaglandins that normally maintain renal afferent arteriole tone and promote natriuresis. NSAID-mediated prostaglandin inhibition causes sodium and water retention, increases renal vascular resistance, reduces the antihypertensive effect of ACE inhibitors (which depend on renal prostaglandins for part of their BP-lowering mechanism), and can precipitate acute kidney injury in patients with CKD — this patient's eGFR of 42 makes her particularly vulnerable. Pseudoephedrine is a direct- and indirect-acting sympathomimetic that causes alpha-1-mediated vasoconstriction, raising systemic vascular resistance and BP — it is a well-recognized and commonly missed cause of drug-induced hypertension. The combination of both agents in a patient with CKD, diabetes, and already-maximal antihypertensive therapy is sufficient to explain the BP breakthrough. The appropriate response is to discontinue both agents and substitute acetaminophen for pain and a saline nasal rinse or intranasal corticosteroid for congestion.

Option B: Option B is incorrect — lisinopril does not cause paradoxical BP elevation through RAAS overstimulation at 40 mg; 40 mg is the maximum recommended dose and ceiling effects reduce incremental benefit, but paradoxical hypertension from ACE inhibitor overdose does not occur through this mechanism.
Option C: Option C is incorrect — metformin's mechanism (mitochondrial complex I inhibition reducing hepatic gluconeogenesis) does not increase peripheral vascular resistance; metformin has no significant BP effect.
Option D: Option D is incorrect — CCBs do not develop pharmacokinetic tachyphylaxis through L-type channel downregulation in the manner described.
Option E: Option E is incorrect — statins enhance rather than reduce endothelial NO synthesis; they do not cause hypertension.

6. [CASE 2 — QUESTION 2] Both ibuprofen and pseudoephedrine are discontinued. Two weeks later, her BP has improved to 156/94 mmHg but remains above goal. Her potassium is now 5.1 mEq/L and creatinine is 1.5 mg/dL. Her physician wants to add a fourth antihypertensive. Given her stage of CKD (eGFR 42), diabetic nephropathy with significant albuminuria (ACR 340 mg/g), and borderline hyperkalemia, which of the following represents the most evidence-based and safest fourth agent?

A) Add spironolactone 25 mg daily because PATHWAY-2 (a randomized crossover trial demonstrating spironolactone superiority as a fourth-line agent in resistant hypertension) supports mineralocorticoid receptor (MR) antagonism as the most evidence-based fourth-line choice in all patients
B) Add hydrochlorothiazide 25 mg daily to provide additional volume reduction and lower her potassium, which addresses both the residual BP elevation and the borderline hyperkalemia simultaneously
C) Add a beta-blocker such as carvedilol because it provides additional BP lowering through combined alpha-1 and beta-1 blockade and reduces renal sympathetic outflow without affecting potassium homeostasis
D) Add finerenone, a non-steroidal mineralocorticoid receptor antagonist shown in the FIDELIO-DKD (finerenone in CKD with type 2 diabetes — renal outcomes) and FIGARO-DKD (finerenone in CKD with type 2 diabetes — cardiovascular outcomes) trials to reduce cardiovascular events and slow CKD progression in patients with type 2 diabetes and albuminuric CKD, with a lower risk of hyperkalemia than spironolactone; alternatively, a low-dose thiazide-like diuretic could provide additional volume control and lower serum potassium
E) Add an ARB such as losartan to achieve dual RAAS blockade — combining an ACE inhibitor with an ARB provides additive reduction in albuminuria and BP in diabetic nephropathy, and the ONTARGET trial supports this combination in high-risk patients

ANSWER: D

Rationale:

This question asked you to select the most appropriate and safe fourth antihypertensive agent in a patient with diabetic CKD, significant albuminuria, and borderline hyperkalemia. Option D is correct: finerenone is a non-steroidal, highly selective mineralocorticoid receptor antagonist that was evaluated specifically in patients with type 2 diabetes and CKD with albuminuria in the FIDELIO-DKD trial (which demonstrated reduced risk of kidney failure and cardiovascular events) and the FIGARO-DKD trial (which demonstrated reduced cardiovascular mortality). Unlike spironolactone and eplerenone (steroidal MR antagonists), finerenone has a distinct tissue distribution and receptor binding profile that produces meaningful cardiorenal protection with a lower incidence of hyperkalemia — a critical advantage in a patient with CKD and already-borderline potassium of 5.1 mEq/L. If finerenone is not available or accessible, adding a low-dose thiazide-like diuretic to provide volume control and lower serum potassium is a clinically reasonable alternative. option fails to acknowledge this critical safety limitation.

Option A: Option A is incorrect as stated: while spironolactone is the PATHWAY-2-supported fourth-line agent for resistant hypertension broadly, adding it to a patient on an ACE inhibitor with eGFR 42 and potassium already 5.1 mEq/L carries significant hyperkalemia risk — the
Option B: Option B is incorrect — hydrochlorothiazide 25 mg provides less cardiovascular outcome benefit than chlorthalidone, and while a thiazide would help potassium, the preferred choice in diabetic albuminuric CKD is an agent with specific cardiorenal protective evidence.
Option C: Option C is incorrect — carvedilol provides additional BP lowering but has no specific renal protective evidence in this setting and the alpha-1 blockade component raises orthostatic hypotension concerns.
Option E: Option E is incorrect and potentially harmful — dual RAAS blockade combining an ACE inhibitor and ARB was evaluated in ONTARGET (ramipril plus telmisartan versus either alone) and showed no additional cardiovascular benefit with significantly more adverse effects including AKI and hyperkalemia; this combination is not recommended.

7. [CASE 2 — QUESTION 3] Ms. K.M. is started on a low-dose thiazide-like diuretic and her BP improves to 132/80 mmHg over the following 2 months. Her creatinine has stabilized at 1.5 mg/dL and potassium at 4.7 mEq/L. Her physician notices she is on metformin with an eGFR of 42. Which of the following correctly addresses the safety of continued metformin use at this eGFR, and what is the pharmacological basis for the concern?

A) Metformin must be discontinued immediately at any eGFR below 60 mL/min/1.73m² because renal tubular accumulation of metformin causes direct nephrotoxicity that accelerates CKD progression
B) Metformin can be continued safely at eGFR 42 with dose reduction and monitoring — current FDA guidance allows metformin use with caution down to eGFR 30 mL/min/1.73m²; the concern is not nephrotoxicity but the risk of metformin accumulation leading to lactic acidosis, because metformin is renally excreted and reduced eGFR impairs its clearance, raising plasma lactate levels through mitochondrial complex I inhibition that reduces hepatic lactate metabolism
C) Metformin has no renal safety concerns at any level of eGFR because it is hepatically metabolized by CYP2C8 and does not accumulate in renal impairment
D) Metformin should be discontinued and replaced with an SGLT-2 (sodium-glucose cotransporter-2) (sodium-glucose cotransporter-2) inhibitor such as empagliflozin because SGLT-2 inhibitors have both antihyperglycemic and cardiorenal protective effects that are superior to metformin at any level of CKD
E) Metformin causes hyperkalemia through potassium redistribution from hepatocytes, and her borderline potassium of 4.7 mEq/L is attributable to metformin toxicity at this eGFR — discontinuation is required to normalize potassium before antihypertensive adjustments are made

ANSWER: B

Rationale:

This question asked you to apply the pharmacological basis for metformin safety concerns in CKD and identify the correct FDA guidance. Option B is correct: the primary safety concern with metformin in CKD is not nephrotoxicity — metformin does not damage the kidney. The concern is metformin accumulation due to impaired renal clearance, which raises plasma metformin levels and secondarily raises the risk of lactic acidosis. Metformin inhibits mitochondrial complex I (reducing oxidative phosphorylation) which increases hepatic lactate production; normally this is metabolized rapidly, but at elevated plasma metformin concentrations in patients with CKD and particularly in states of reduced hepatic perfusion (dehydration, acute illness, contrast administration), lactate accumulation can become clinically significant. The FDA updated its labeling to allow metformin use with caution and dose reduction when eGFR is 30–45 mL/min/1.73m², and to continue without restriction from 45–60 mL/min/1.73m². At eGFR 42, metformin can be continued at reduced dose with monitoring of renal function and avoidance of situations that further reduce perfusion.

Option A: Option A is incorrect — the FDA threshold for mandatory metformin discontinuation is eGFR below 30 mL/min/1.73m², not 60 mL/min/1.73m²; the older, more conservative guidance (discontinue below eGFR 60) has been updated.
Option C: Option C is incorrect — metformin is not hepatically metabolized; it is renally excreted unchanged, which is precisely why CKD causes accumulation.
Option D: Option D is incorrect — SGLT-2 inhibitors are excellent adjunctive therapy in this patient, but they should be added rather than used as a reason to eliminate metformin; the two are complementary.
Option E: Option E is incorrect — metformin does not cause hyperkalemia through potassium redistribution from hepatocytes; this mechanism is fabricated.

8. [CASE 2 — QUESTION 4] At a subsequent visit, Ms. K.M.'s physician notes her urine ACR has decreased from 340 to 180 mg/g over 6 months of optimized therapy. She asks whether this improvement in her urine protein means her kidneys are getting better and whether she will need dialysis. Which of the following most accurately frames the clinical significance of the ACR reduction and its relationship to long-term renal prognosis?

A) The ACR reduction confirms complete reversal of her diabetic nephropathy — proteinuria at this level indicates the glomerular filtration barrier has fully healed and no further pharmacological intervention is needed beyond maintaining current BP control
B) The improvement in ACR reflects improvement in glycemic control from metformin alone and is unrelated to the antihypertensive regimen — the RAAS blockade and thiazide have no effect on albuminuria
C) The ACR reduction is pharmacologically insignificant — a decrease from 340 to 180 mg/g remains in the severely albuminuric range and indicates treatment failure; escalation to dialysis preparation should begin immediately
D) The ACR reduction means her kidneys are fully recovered and RAAS blockade can be discontinued now that the proteinuria target has been achieved — continuing lisinopril beyond this point risks over-suppression of intraglomerular pressure and paradoxical GFR decline
E) Reduction in urine ACR from 340 to 180 mg/g is a clinically meaningful response to pharmacological therapy — it reflects reduced intraglomerular pressure and improved glomerular filtration barrier integrity — and reduction in albuminuria is an established surrogate marker associated with slower GFR decline and reduced risk of progression to end-stage renal disease (ESRD); however, diabetic nephropathy is not reversed by pharmacological therapy — the goal is slowing progression, not curing the underlying disease, and continued vigilance with BP control, RAAS blockade, glucose optimization, and avoidance of nephrotoxins is essential

ANSWER: E

Rationale:

This question asked you to interpret the clinical significance of ACR reduction and frame it accurately for the patient. Option E is correct: a reduction in urine ACR from 340 to 180 mg/g — a 47% decrease — is a clinically meaningful response to pharmacological therapy. Albuminuria reduction is one of the most robust surrogate markers for long-term renal outcomes in diabetic nephropathy; patients who achieve greater reductions in albuminuria with RAAS blockade have consistently slower rates of GFR decline and lower risks of doubling of serum creatinine and ESRD in landmark trials. However, it is critical to communicate accurately that pharmacological therapy slows progression of diabetic nephropathy — it does not reverse the underlying structural damage to the glomerulus (mesangial expansion, basement membrane thickening, podocyte loss). Continued optimization of BP, RAAS blockade, glycemic control, and avoidance of nephrotoxins (NSAIDs, contrast media without adequate hydration, excessive sodium) remains essential. The honest answer to her question about dialysis is that her current trajectory — with reduced albuminuria and stable creatinine on optimal therapy — is favorable, but CKD from diabetes is progressive, and the goal is to delay rather than eliminate the risk of ESRD.

Option A: Option A is incorrect — pharmacological therapy does not fully heal the glomerular filtration barrier; the structural changes of diabetic nephropathy are not reversible.
Option C: Option C is incorrect — while 180 mg/g remains in the moderately-to-severely albuminuric range, a 47% reduction in response to therapy is a positive prognostic sign, not treatment failure; immediate dialysis preparation is not indicated.
Option D: Option D is incorrect — RAAS blockade should not be discontinued when albuminuria targets are achieved; it is continued indefinitely because the renal protective benefit depends on sustained efferent vasodilation and reduced intraglomerular pressure.
Option B: Option B is incorrect — RAAS blockade reduces albuminuria through intraglomerular pressure reduction, independent of glycemic control; this is one of the primary mechanisms of renoprotection.

CASE 3

Mr. D.W. is a 34-year-old man who presents to the emergency department with a 3-day history of progressively worsening headache, visual disturbances, and confusion. He has no known medical history and takes no medications. On examination: BP 228/148 mmHg bilaterally, heart rate 104 bpm, respiratory rate 18, temperature 37.1°C. He is disoriented to time and place. Funduscopic examination reveals bilateral flame hemorrhages, cotton-wool spots, and papilledema. Serum creatinine is 3.2 mg/dL (no prior baseline). Urinalysis shows 3+ protein and red cell casts. ECG shows left ventricular hypertrophy by voltage criteria.

9. [CASE 3 — QUESTION 1] Which of the following most accurately classifies this presentation and identifies the immediate treatment priority?

A) Hypertensive emergency — BP elevation with acute target organ damage affecting the brain (encephalopathy), kidneys (AKI with red cell casts indicating glomerular injury), and eyes (Grade III-IV retinopathy); the immediate priority is controlled IV antihypertensive therapy targeting a mean arterial pressure (MAP) reduction of approximately 10–25% in the first hour, with careful avoidance of rapid normalization
B) Hypertensive urgency — BP is elevated but no target organ damage is present; oral antihypertensives can be started and the patient discharged with close outpatient follow-up within 24 hours
C) Hypertensive crisis requiring immediate sodium nitroprusside infusion to normalize BP to below 120/80 mmHg within 30 minutes to prevent irreversible organ damage
D) Malignant hypertension requiring immediate oral amlodipine and lisinopril initiation with same-day discharge, as the oral route provides adequate speed of onset for this presentation
E) Hypertensive pseudocrisis — the elevated BP is a response to pain and anxiety from the headache; after analgesia and anxiolysis the BP will normalize and no specific antihypertensive intervention is required

ANSWER: A

Rationale:

This question asked you to classify Mr. D.W.'s presentation and identify the immediate treatment priority. Option A is correct: this is a hypertensive emergency — severe BP elevation with acute, clinically apparent target organ damage. The triad of neurological changes (confusion, disorientation = hypertensive encephalopathy), acute kidney injury with red cell casts (suggesting severe glomerular injury from malignant nephrosclerosis), and Grade III-IV hypertensive retinopathy (bilateral flame hemorrhages, cotton-wool spots, papilledema) constitutes multi-organ hypertensive emergency. The correct immediate approach is intravenous antihypertensive therapy with a titratable agent — labetalol, nicardipine, or clevidipine are preferred in most settings — targeting a MAP reduction of approximately 10–25% in the first hour, then more gradual reduction over 24–48 hours. Rapid normalization of BP is explicitly contraindicated because organs adapted to chronic hypertension have reset their autoregulatory ranges upward; precipitous BP reduction below the autoregulatory threshold causes ischemic injury to the brain, kidneys, and coronary circulation.

Option B: Option B is incorrect — multiple target organ damage findings are present; this is not urgency (elevated BP without acute organ damage).
Option C: Option C is incorrect — rapid normalization to below 120/80 mmHg within 30 minutes is the wrong target and wrong timeline; sodium nitroprusside is one available IV agent but the target reduction is 10–25% of MAP in the first hour, not full normalization.
Option D: Option D is incorrect — oral agents have inadequate onset speed and titratability for this presentation; same-day discharge is entirely inappropriate.
Option E: Option E is incorrect — the neurological changes, funduscopic findings, red cell casts, and degree of BP elevation cannot be attributed to pain and anxiety.

10. [CASE 3 — QUESTION 2] Mr. D.W. is admitted to the ICU and started on IV labetalol. Over 6 hours, MAP is reduced by 20% and his confusion clears. Further history obtained from his partner reveals he stopped taking prescribed medications approximately 3 months ago. Workup reveals plasma renin activity markedly elevated at 18 ng/mL/hr, plasma aldosterone 42 ng/dL, and renal Doppler ultrasound showing high-velocity turbulent flow in the right renal artery. Which secondary cause does this workup most strongly suggest, and what are the pharmacological implications for his long-term management?

A) Primary aldosteronism from a right adrenal adenoma — the elevated renin is a false positive from the acute hypertensive crisis; long-term management is with spironolactone
B) Cushing syndrome — the elevated renin reflects cortisol-mediated RAAS activation; long-term management is with ketoconazole to suppress cortisol synthesis
C) Pheochromocytoma — the elevated renin reflects catecholamine-driven juxtaglomerular stimulation; long-term management requires alpha-blockade before beta-blockade
D) Renovascular hypertension from right renal artery stenosis — elevated renin confirms RAAS activation from reduced right renal perfusion; long-term pharmacological management must avoid ACE inhibitors and ARBs if bilateral disease is confirmed or if the contralateral kidney is functionally dependent on the stenotic side, as RAAS blockade will precipitate AKI
E) Drug-induced hypertension from a sympathomimetic — the markedly elevated renin and Doppler findings are coincidental; the primary issue is resumption of his previously prescribed antihypertensives

ANSWER: D

Rationale:

This question asked you to interpret the secondary workup findings and identify the pharmacological implications. Option D is correct: the combination of markedly elevated plasma renin activity and high-velocity turbulent flow in the right renal artery on Doppler is the diagnostic pattern of renovascular hypertension. Right renal artery stenosis reduces perfusion pressure distal to the stenosis, chronically stimulating juxtaglomerular renin secretion — explaining the markedly elevated plasma renin activity (PRA) of 18 ng/mL/hr (in contrast to primary aldosteronism, where autonomous aldosterone suppresses renin). The pharmacological implication is critical: if the left renal artery is normal (unilateral stenosis), ACE inhibitors or ARBs can be used cautiously — the contralateral kidney can maintain GFR without efferent compensatory constriction. However, if the patient has bilateral renal artery stenosis, or stenosis to a solitary functioning kidney, both ACE inhibitors and ARBs are contraindicated because GFR maintenance on both sides depends on efferent arteriole constriction from Ang II, and RAAS blockade precipitates AKI. Given his creatinine of 3.2 mg/dL in the acute setting, careful evaluation for bilateral disease before any RAAS inhibitor is used is essential. Revascularization (angioplasty with or without stenting) should be evaluated given his age and the severity of presentation.

Option A: Option A is incorrect — primary aldosteronism presents with suppressed renin, not markedly elevated renin; the Doppler finding does not support adrenal pathology.
Option C: Option C is incorrect — pheochromocytoma would present with elevated plasma metanephrines and episodic symptoms; while catecholamines do stimulate renin, the Doppler finding is the defining abnormality here.
Option B: Option B is incorrect — Cushing syndrome presents with cortisol excess features and does not explain the renal artery Doppler abnormality.
Option E: Option E is incorrect — markedly elevated renin and renal artery Doppler findings are not coincidental; they represent the mechanistic basis for this patient's hypertension.

11. [CASE 3 — QUESTION 3] Renal MR angiography confirms high-grade (85%) right renal artery stenosis from fibromuscular dysplasia (FMD) with a normal left renal artery. Given that the stenosis is unilateral and the contralateral kidney is normal, which of the following correctly describes the appropriate antihypertensive approach while awaiting definitive revascularization?

A) ACE inhibitors are absolutely contraindicated in unilateral renal artery stenosis because efferent vasodilation on the affected side will cause the same AKI as in bilateral disease
B) Calcium channel blockers and beta-blockers are the preferred agents in unilateral renal artery stenosis; ACE inhibitors and ARBs carry a small but real risk of AKI and should be avoided in all forms of renal artery stenosis regardless of laterality
C) In unilateral renal artery stenosis with a normal contralateral kidney, ACE inhibitors or ARBs can be used with careful monitoring — the normal contralateral kidney can maintain overall GFR without efferent compensatory constriction, making RAAS blockade safer than in bilateral disease; however, a modest creatinine rise is still possible and renal function should be monitored closely after initiation
D) Sodium restriction alone is sufficient BP management in unilateral FMD pending revascularization because FMD-related hypertension is entirely volume-dependent and does not respond to pharmacological agents
E) Immediate high-dose oral hydralazine is the preferred bridge therapy in unilateral renal artery stenosis because direct vasodilation bypasses the RAAS entirely and provides BP control without any effect on renal perfusion

ANSWER: C

Rationale:

This question asked you to distinguish the pharmacological approach in unilateral versus bilateral renal artery stenosis. Option C is correct: the key distinction is that in unilateral renal artery stenosis with a normal contralateral kidney, RAAS blockade is not absolutely contraindicated. The normal contralateral kidney is not dependent on Ang II-mediated efferent constriction to maintain its GFR — its perfusion pressure is normal and autoregulation is intact. ACE inhibitors or ARBs can therefore be used, with the important caveat that a modest creatinine rise is still possible from the affected (stenotic) side where efferent tone is reduced, and renal function should be monitored closely after initiation. This is a meaningful clinical distinction — many patients with unilateral renal artery stenosis are appropriately managed with RAAS inhibitors as part of their antihypertensive regimen, particularly given the renal protective and cardiovascular outcome benefits of these agents.

Option A: Option A is incorrect — unilateral renal artery stenosis with a normal contralateral kidney is not an absolute contraindication to ACE inhibitors or ARBs; bilateral disease or stenosis to a solitary kidney is the critical contraindication.
Option B: Option B is incorrect — RAAS blockade is not contraindicated in all forms of renal artery stenosis; the distinction between unilateral and bilateral is clinically important and should not be collapsed.
Option D: Option D is incorrect — FMD-related renovascular hypertension is RAAS-mediated (driven by elevated renin from reduced perfusion pressure), not purely volume-dependent; sodium restriction alone is insufficient.
Option E: Option E is incorrect — hydralazine is not a standard bridge therapy for this indication and has no specific advantage in renovascular hypertension; the rationale that it "bypasses the RAAS entirely" is misleading.

12. [CASE 3 — QUESTION 4] Mr. D.W. undergoes successful percutaneous transluminal renal angioplasty of the right renal artery. At 3-month follow-up, his BP has improved to 138/86 mmHg on amlodipine 10 mg and lisinopril 10 mg daily. His creatinine has improved to 1.8 mg/dL and repeat urine shows resolved red cell casts with trace protein. His plasma renin activity has fallen from 18 to 2.1 ng/mL/hr. He asks whether he will need to take blood pressure medications forever. Which of the following most accurately addresses this question?

A) He can discontinue all medications immediately because successful angioplasty has cured the underlying cause of his hypertension and BP will remain normal without pharmacological support
B) The fall in plasma renin activity from 18 to 2.1 ng/mL/hr confirms complete cure and all antihypertensives should be discontinued at this visit; continued medication use after normalization of renin is harmful because iatrogenic hypotension damages the previously stenotic renal artery
C) He must remain on lisinopril indefinitely regardless of BP outcomes because ACE inhibitors prevent FMD recurrence by blocking Ang II-mediated vascular smooth muscle proliferation in the renal artery wall
D) Revascularization often markedly improves BP control and may reduce the antihypertensive medication burden, but hypertension does not always fully resolve after FMD angioplasty — factors including the duration of hypertension before revascularization, the degree of established secondary vascular remodeling, and whether any element of primary hypertension coexists all influence whether medications can eventually be reduced or eliminated; a gradual supervised reduction trial is appropriate, but complete medication independence cannot be guaranteed
E) Because his hypertension has been present for years and produced left ventricular hypertrophy (LVH) and significant renal injury, he will definitively require lifelong antihypertensive therapy at current doses regardless of the angioplasty outcome

ANSWER: D

Rationale:

This question asked you to provide an accurate, nuanced prognosis for BP control after successful FMD revascularization. Option D is correct: the outcome of BP control after renal artery revascularization in FMD is variable and patient-specific. Young patients with FMD diagnosed early, short duration of hypertension, and minimal end-organ damage have the highest rates of BP cure or significant improvement after angioplasty — some may eventually discontinue all medications. Older patients, those with longer hypertension duration (more established vascular remodeling and possible secondary essential hypertension), and those with significant end-organ damage (as in Mr. D.W. — LVH, prior creatinine of 3.2 mg/dL) have lower rates of complete medication independence. The fall in renin is a positive prognostic sign but does not guarantee complete BP normalization. The appropriate management is ongoing BP monitoring, with a cautious supervised trial of medication reduction if BP remains consistently well-controlled.

Option A: Option A is incorrect — immediate discontinuation of all medications after angioplasty is inappropriate; BP must be monitored for weeks to months before any reduction is attempted.
Option C: Option C is incorrect — ACE inhibitors do not prevent FMD recurrence through anti-proliferative mechanisms in the manner described; this is pharmacologically fabricated.
Option B: Option B is incorrect — normalization of renin is a positive indicator but does not mandate immediate discontinuation of all antihypertensives; and continued medication use does not cause harm to the revascularized artery.
Option E: Option E is incorrect — while his end-organ damage burden suggests a lower chance of complete medication independence, definitive lifelong requirement at current doses cannot be stated with certainty before a supervised reduction trial is attempted.

CASE 4

Ms. J.P. is a 29-year-old woman at 28 weeks of gestation with her first pregnancy. She presents to her obstetrician with BP readings of 162/108 mmHg on two occasions 6 hours apart. She has 2+ proteinuria on dipstick and reports a persistent frontal headache and blurred vision for the past 24 hours. She has no prior history of hypertension. Her labs show platelets 142,000/μL (low normal), LFTs mildly elevated (AST 62 U/L), creatinine 0.9 mg/dL. She is at 28 weeks of gestation.

13. [CASE 4 — QUESTION 1] Which of the following most accurately classifies her presentation and identifies the immediate pharmacological priorities?

A) Severe preeclampsia — BP ≥160/110 mmHg with proteinuria, neurological symptoms (headache, visual changes), and laboratory abnormalities (thrombocytopenia, elevated LFTs) constitute severe features; immediate priorities are antihypertensive therapy to reduce the risk of maternal hemorrhagic stroke and magnesium sulfate for seizure prophylaxis
B) Gestational hypertension without preeclampsia — her BP elevation is consistent with the normal cardiovascular adaptation to pregnancy; antihypertensive therapy is not indicated until BP exceeds 180/120 mmHg
C) HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets) requiring immediate delivery by cesarean section without time for pharmacological stabilization
D) Chronic hypertension unmasked by pregnancy — the proteinuria and laboratory changes are pre-existing and not related to gestational hypertension; standard outpatient antihypertensive initiation is appropriate
E) Preeclampsia without severe features — the BP and laboratory findings represent mild preeclampsia that can be managed expectantly with close monitoring without immediate antihypertensive intervention

ANSWER: A

Rationale:

This question asked you to classify Ms. J.P.'s presentation and identify immediate pharmacological priorities. Option A is correct: this presentation meets criteria for severe preeclampsia. Severe features include any one of: BP ≥160/110 mmHg on two occasions at least 4 hours apart (met — 162/108 mmHg), neurological symptoms (headache and visual disturbances are present — these are warning signs of impending eclampsia), thrombocytopenia (platelets 142,000 — low normal, concerning), and elevated liver enzymes. Two immediate pharmacological priorities exist simultaneously: antihypertensive therapy to reduce the risk of maternal hemorrhagic stroke (the most dangerous immediate consequence of severe hypertension in pregnancy) targeting BP below 160/110 mmHg, and magnesium sulfate (MgSO4) for seizure prophylaxis in severe preeclampsia, which is not an antihypertensive but a neuroprotective agent that prevents progression to eclamptic seizures.

Option B: Option B is incorrect — this is not normal cardiovascular adaptation; proteinuria, neurological symptoms, and laboratory abnormalities define pathological preeclampsia.
Option C: Option C is incorrect — while HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome may be developing, immediate cesarean without pharmacological stabilization is not appropriate; stabilization with antihypertensives and MgSO4 should occur first, and gestational age and severity guide delivery timing decisions.
Option D: Option D is incorrect — new-onset proteinuria after 20 weeks with severe BP and neurological symptoms in a patient without prior hypertension is preeclampsia, not pre-existing chronic disease.
Option E: Option E is incorrect — the presence of BP ≥160/110 mmHg, neurological symptoms, and laboratory abnormalities constitute severe features by definition, moving this beyond mild preeclampsia.

14. [CASE 4 — QUESTION 2] The obstetrics team initiates IV magnesium sulfate and needs to acutely lower her BP. Which of the following antihypertensive agents is appropriate for acute IV management of severe hypertension in pregnancy, and which agent is absolutely contraindicated?

A) IV sodium nitroprusside is preferred for acute BP reduction in pregnancy; ACE inhibitors are contraindicated only in the first trimester
B) Oral hydralazine 25 mg is preferred because the oral route avoids the risk of precipitous BP drop associated with IV administration, and there are no contraindicated agents in acute severe hypertension in pregnancy
C) IV enalaprilat (IV ACE inhibitor) is the preferred agent because RAAS blockade prevents placental aldosterone-mediated sodium retention, directly addressing the mechanism of preeclampsia
D) IV nicardipine is the only approved antihypertensive for acute use in pregnancy; all other IV agents including labetalol are contraindicated due to fetal bradycardia risk
E) IV labetalol or IV hydralazine or oral nifedipine immediate-release are appropriate acute antihypertensives in pregnancy; ACE inhibitors and ARBs are absolutely contraindicated due to fetal renal tubular dysplasia, oligohydramnios, and skull ossification defects mediated by blockade of the fetal RAAS during critical developmental periods

ANSWER: E

Rationale:

This question asked you to identify the appropriate acute antihypertensives in pregnancy and the absolute contraindication. Option E is correct: for acute management of severe hypertension in pregnancy, the accepted agents are IV labetalol (combined alpha/beta-blocker — extensive safety record in pregnancy), IV hydralazine (direct vasodilator — long-established use, though associated with more maternal hypotension than labetalol in some comparisons), and oral immediate-release nifedipine (dihydropyridine CCB — evidence supports comparable efficacy to IV agents, preferred by some guidelines for its simplicity). ACE inhibitors and ARBs are absolutely contraindicated throughout pregnancy after the first trimester. The mechanism of harm is fetal RAAS blockade during critical periods of renal development: the fetal kidney depends on Ang II to maintain renal perfusion pressure and normal tubular function; ACE inhibitor or ARB exposure in the second and third trimesters causes fetal renal tubular dysplasia, fetal anuria, oligohydramnios (reduced amniotic fluid from fetal anuria), pulmonary hypoplasia (from reduced fetal breathing movements in oligohydramnios), and calvaria (skull) hypoplasia. This is a class-wide teratogenic effect with a black-box warning.

Option A: Option A is incorrect — IV sodium nitroprusside carries risk of fetal cyanide toxicity (from cyanide metabolites) and is a last-resort agent in pregnancy, not preferred; and ACE inhibitors are contraindicated throughout pregnancy after the first trimester, not only in the first trimester.
Option C: Option C is incorrect and dangerous — IV enalaprilat is an ACE inhibitor and is absolutely contraindicated in pregnancy regardless of route of administration.
Option D: Option D is incorrect — IV nicardipine is an acceptable agent but is not the only approved option; labetalol is widely used and does not carry an absolute fetal bradycardia contraindication.
Option B: Option B is incorrect — oral hydralazine has slower onset and less predictable absorption than IV formulations in acute severe hypertension; and ACE inhibitors and ARBs are absolutely contraindicated, making Option B's contraindication statement essential clinical knowledge.

15. [CASE 4 — QUESTION 3] After acute BP stabilization with IV labetalol, the team transitions Ms. J.P. to oral antihypertensives for ongoing management of her severe preeclampsia at 28 weeks. Delivery is planned for 34 weeks unless clinical deterioration occurs. Which of the following oral antihypertensive regimens is most appropriate for BP maintenance in this setting?

A) Lisinopril 10 mg daily and amlodipine 5 mg daily — this combination provides reliable BP control with minimal fetal risk
B) Methyldopa 250 mg three times daily — methyldopa is the only acceptable antihypertensive in pregnancy because all other classes carry teratogenic risk
C) Labetalol 200 mg twice daily or nifedipine extended-release 30 mg daily, either as monotherapy or in combination — both have established safety profiles in pregnancy; methyldopa remains an acceptable alternative, particularly for patients who were already on it before pregnancy
D) Metoprolol succinate 50 mg daily — beta-1 selective blockade is preferred in pregnancy because non-selective agents such as labetalol carry higher fetal risk through beta-2 blockade of uterine relaxation
E) Amlodipine 10 mg daily alone — dihydropyridine CCBs are the only class recommended in pregnancy after 28 weeks because all other classes have been associated with preterm labor

ANSWER: C

Rationale:

This question asked you to identify the appropriate oral antihypertensive regimen for ongoing management of severe preeclampsia. Option C is correct: the accepted oral antihypertensives for use in pregnancy include labetalol (combined alpha/beta-blocker — widely used, good evidence base), nifedipine extended-release (dihydropyridine CCB — evidence supports safety and efficacy in pregnancy, preferred by many contemporary guidelines), and methyldopa (central alpha-2 agonist — the longest safety record in pregnancy, with follow-up data on offspring extending to school age). These agents can be used as monotherapy or in combination when BP control requires more than one agent. The target BP in severe preeclampsia management is generally 130–150/80–100 mmHg — tight enough to reduce stroke risk while avoiding hypotension that could compromise uteroplacental perfusion.

Option A: Option A is incorrect and dangerous — lisinopril is an ACE inhibitor and is absolutely contraindicated in pregnancy due to fetal RAAS-mediated teratogenicity.
Option B: Option B is incorrect — methyldopa is an acceptable agent but is not the only acceptable antihypertensive in pregnancy; labetalol and nifedipine are equally accepted and preferred by many practitioners because of methyldopa's side effect profile (sedation, depression).
Option D: Option D is incorrect — while metoprolol succinate is used in some pregnant patients, the framing that non-selective beta-blockers carry higher fetal risk through beta-2 blockade of uterine relaxation is not the established clinical concern; labetalol's combined alpha/beta-blockade profile makes it favorable, and it is not contraindicated.
Option E: Option E is incorrect — amlodipine is a reasonable agent but is not the only recommended class after 28 weeks, and the claims about other classes causing preterm labor are not supported by current evidence.

16. [CASE 4 — QUESTION 4] Ms. J.P. delivers at 33 weeks due to clinical deterioration. She breastfeeds her infant. Her BP at 6 weeks postpartum remains elevated at 148/94 mmHg. She asks which antihypertensive agents are safe to continue while breastfeeding. Which of the following most accurately addresses this question?

A) All antihypertensives are contraindicated during breastfeeding because any antihypertensive drug will cause neonatal hypotension through breast milk transfer; formula feeding is required if BP treatment is needed
B) ACE inhibitors can now be safely initiated postpartum — the teratogenic concern applies only in utero; in the postpartum breastfeeding period, ACE inhibitors have minimal transfer into breast milk and several (particularly enalapril and captopril) are considered compatible with breastfeeding by most guidelines
C) Only methyldopa is safe during breastfeeding; all other antihypertensives transfer into breast milk at levels that cause significant neonatal harm
D) Labetalol, nifedipine, and methyldopa — agents used during pregnancy — remain appropriate postpartum options; ACE inhibitors such as enalapril and captopril are also considered compatible with breastfeeding due to minimal breast milk transfer and poor neonatal oral absorption; the absolute contraindication to ACE inhibitors applies in utero, not postpartum
E) Diuretics are the only safe class postpartum because they do not transfer into breast milk; all other agents including labetalol and ACE inhibitors are contraindicated in lactating women

ANSWER: D

Rationale:

This question asked you to correctly apply the distinction between in utero teratogenicity and postpartum breastfeeding safety for antihypertensives. Option D is correct: the absolute contraindication to ACE inhibitors and ARBs applies to in utero fetal exposure — the fetal RAAS is critical to normal renal development in the second and third trimesters, and transplacental RAAS blockade during organogenesis causes the described teratogenic effects. Postpartum breastfeeding is a fundamentally different exposure route: antihypertensives present in breast milk are ingested orally by the neonate, who has a functioning and mature GI tract and hepatic first-pass metabolism. ACE inhibitors such as enalapril and captopril have minimal transfer into breast milk (very low milk-to-plasma ratios) and poor oral bioavailability in neonates, making neonatal systemic exposure negligible. Both are considered compatible with breastfeeding by the WHO and major lactation references. Labetalol, nifedipine, and methyldopa — used during pregnancy — remain appropriate postpartum. ARBs, in contrast, have less data in lactation and are generally avoided. Option B is partially correct but incomplete — while ACE inhibitors can be initiated postpartum during breastfeeding, the explanation that "the teratogenic concern applies only in utero" without acknowledging the distinction makes the option less complete than Option D.

Option A: Option A is incorrect — antihypertensives are not universally contraindicated during breastfeeding; many are compatible with lactation.
Option C: Option C is incorrect — the restriction to methyldopa alone is unnecessarily narrow; multiple agents are safe during breastfeeding.
Option E: Option E is incorrect — diuretics are actually used cautiously in breastfeeding because they may reduce milk supply; and the claim that labetalol and ACE inhibitors are contraindicated in lactating women is incorrect.